Clinical Trial Search

Primary: Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter…

Primary: Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. — -0.017 ratio — p=0.612

Primary: Fluctuation in Pupil Diameter (Hippus) -Pre Drug Administration — 1.61; 1.71 milliseconds^2 — p=0.64

Primary: Incidence of Postoperative Residual Neuromuscular Blockade at Time of Arrival to the Post-anesthesia Care Unit. — 5 Participants

Primary: Percent Change in Pain Assessed by Visual Analogue Scale (VAS) — -0.0145; -0.2082; -0.1109 percentage of pain change

Primary: Improvement in Oxygenation — 25.7; 29.7 ratio

Primary: DB Period: Percent Change From Baseline in Sleep Quality Numerical Rating Scale (NRS) at Week 12 — -47.71; -32.98 percent change — p=<0.001

Primary: Incidence of Postoperative Residual Neuromuscular Blockade at Time of Extubation — 0 Participants

Primary: Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM — -10.72; 1.94; -3.34; 1.56 mmHg

Primary: Frequency of Muscle Cramps as Assessed by Patient Survey — 1.14; 1.23 score on a scale

Primary: Mean Visual Analog Scores — 4; 3.5; 4; 3.5 score on a scale

Primary: Number of Participants With Optimal Arterial Waveform — 27; 18 Participants

Primary: Percentage of Participants Achieving Meaningful Asthma Improvement at the End of 12-Week Treatment Period — 54.6; 61.33 percentage of participants

Primary: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) — 1420 Participants

Primary: Change From Baseline in Vascular Inflammation as Measured by FDG-PET/CT at 6 Months — -0.19; -0.24 ratio — p=0.79